HTML Microdata document

This HTML5 document contains 41 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n11	http://linked.opendata.cz/resource/drugbank/drug/DB04960/identifier/chemspider/
n7	http://bio2rdf.org/drugbank:
adms	http://www.w3.org/ns/adms#
n9	http://linked.opendata.cz/resource/drugbank/drug/DB04960/identifier/pubchem-compound/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n10	http://linked.opendata.cz/resource/drugbank/drug/DB04960/identifier/pubchem-substance/
owl	http://www.w3.org/2002/07/owl#
n3	http://linked.opendata.cz/ontology/drugbank/
n12	http://linked.opendata.cz/resource/drugbank/drug/DB04960/identifier/drugbank/
n4	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#

Statements

Subject Item: n2:DB04960
rdf:type: n3:Drug
n3:description: R115777 is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called tipifarnib and Zarnestra.
n3:generalReferences: # Martin LA, Head JE, Pancholi S, Salter J, Quinn E, Detre S, Kaye S, Howes A, Dowsett M, Johnston SR: The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. Mol Cancer Ther. 2007 Sep;6(9):2458-67. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17876043 # Wang CC, Liao YP, Mischel PS, Iwamoto KS, Cacalano NA, McBride WH: HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway. Cancer Res. 2006 Jul 1;66(13):6756-62. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16818651
n3:group: investigational
n3:indication: Investigated for use/treatment in colorectal cancer, leukemia (myeloid), pancreatic cancer, and solid tumors.
owl:sameAs: n7:DB04960
dcterms:title: R115777
adms:identifier: n9:159324 n10:10253567 n11:140122 n12:DB04960
n3:mechanismOfAction: The farnesyltransferase inhibitors (FTIs) are a class of experimental cancer drugs that target protein farnesyltransferase with the downstream effect of preventing the proper functioning of the Ras protein, which is commonly abnormally active in cancer. After translation, RAS goes through four steps of modification: isoprenylation, proteolysis, methylation and palmitoylation. Isoprenylation involves the enzyme farnesyltransferase (FTase) transferring a farnesyl group from farnesyl pyrophosphate (FPP) to the pre-RAS protein. Also, a related enzyme geranylgeranyltransferase I (GGTase I) has the ability to transfer a geranylgeranyl group to K and N-RAS. Farnesyl is necessary to attach RAS to the cell membrane. Without attachment to the cell membrane, RAS is not able to transfer signals from membrane receptors (Reuter et al., 2000).
n3:synonym: Tipifarnib
n3:IUPAC-Name: n4:271B6146-363D-11E5-9242-09173F13E4C5
n3:InChI: n4:271B614C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula: n4:271B614B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight: n4:271B6148-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight: n4:271B6149-363D-11E5-9242-09173F13E4C5
n3:SMILES: n4:271B614A-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility: n4:271B6144-363D-11E5-9242-09173F13E4C5
n3:logP: n4:271B6142-363D-11E5-9242-09173F13E4C5 n4:271B6145-363D-11E5-9242-09173F13E4C5
n3:logS: n4:271B6143-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count: n4:271B6152-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count: n4:271B6153-363D-11E5-9242-09173F13E4C5
n3:InChIKey: n4:271B614D-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-: n4:271B614E-363D-11E5-9242-09173F13E4C5
n3:Polarizability: n4:271B6150-363D-11E5-9242-09173F13E4C5
n3:Refractivity: n4:271B614F-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count: n4:271B6151-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism: Humans and other mammals
n3:casRegistryNumber: 192185-68-5
n3:category
n3:Bioavailability: n4:271B6157-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter: n4:271B6159-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule: n4:271B615A-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings: n4:271B6156-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge: n4:271B6155-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five: n4:271B6158-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name: n4:271B6147-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-: n4:271B6154-363D-11E5-9242-09173F13E4C5